<DOC>
	<DOCNO>NCT00603356</DOCNO>
	<brief_summary>This Phase I , dose escalation , safety study OSI-930 Erlotinib cancer tumor .</brief_summary>
	<brief_title>Phase I Study OSI-930 Erlotinib Cancer Tumors</brief_title>
	<detailed_description>Multicenter , open-label , phase 1 , dose escalation study determine maximum tolerate dose OSI-930 Erlotinib . Patients may continue receive OSI-930 Erlotinib one follow occurs : disease progression , adverse event require withdrawal , failure recover toxicity despite 14-day dosing interruption , medical ethical reason , patient request , patient death .</detailed_description>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histology cytologically document malignancy advance and/or metastatic refractory establish form therapy effective therapy exist Age great equal 18 year ECOG PS 02 ANC great equal 1.5 x 10^9/L Bilirubin less equal 1.5 x upper limit normal ( ULN ) , AST ALT less equal 2.5 x ULN Creatinine less equal 1.5 ULN Predicted life expectancy great equal 12 week Prior chemotherapy permit provide minimum 3 week elapse Prior tyrosine kinase inhibitor therapy permit Patients must recover treatmentrelated toxicity ( exception ) prior registration Prior hormonal therapy permit provided discontinue prior registration ( exception prostate cancer patient hormone therapy least 3 month ) Prior radiation therapy permit provide exceed 25 % bone marrow reserve patient recover toxic effect ( minimum 21 day must elapse unless radiotherapy palliative nonmyelosuppressive ) Prior surgery permit , provide wound healing occur prior registration Patients must use proactive effective contraceptive measure throughout study Provide write informed consent Accessible repeat dose followup Adequate hematopoietic , hepatic , renal function Significant cardiac disease unless well control Current former smoker , unless patient stop smoke great 3 month prior registration Active uncontrolled infection serious illness medical condition could interfere participation History unacceptable toxicity previous EGFR inhibitor therapy History psychiatric condition might impair patient 's ability provide inform consent participate Use CYP3A4 inducers/inhibitors 14 day prior first dose Pregnant breastfeeding female Symptomatic brain metastasis stable , require steroid , potentially lifethreatening require radiation within last 28 day History allergic reaction attribute similar compound study drug GI abnormalities include inability take oral medication , require IV alimentation Clinically significant ophthalmologic abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>GIST</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Mesothelioma</keyword>
	<keyword>Renal</keyword>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Sarcoma</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Cancer</keyword>
</DOC>